Key Metrics 
10 Yrs X-Ray 
Profit & Loss 
Valuation 
Analyst Note 
Balance Sheet 
Cash Flow 
Financial Ratio 
Qtr. Results 
News 
About
Perk Pharmaceuticals Ltd (530673)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 530673 NSE: Pharmaceuticals & Drugs | Small Cap | Perk Pharma Share Price
BSE Share Price
Not Listed
Not Listed
Perk Pharmaceuticals Ltd (530673)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 530673 NSE: Pharmaceuticals & Drugs | Small Cap | Perk Pharma Share Price
BSE Share Price
Not Listed
Not Listed
Key Metrics
Valuation Multiples
Market Cap
₹1 Cr.
Current Price
₹0
52-Week Low / High
₹0 / 0
TTM EPS
₹0.1
TTM Sales
₹1 Cr.
Book Value per Share
₹9.5
P/E Ratio
18.12
Industry PE
49.7
Price to Book (P/B)
0.21
Price to Sales (P/S)
1.25
EV/EBITDA
4.81
Dividend Yield
NAN%
Profitability Efficiency
Return on Equity (ROE)
1.64%
Return on Capital Employed (ROCE)
1.91%
Return on Assets (ROA)
1.15%
Operating Profit Margin
15.9%
Net Profit Margin
6.88%
Gross Profit Margin
18.9%
Growth Momentum
1-yr vs 3-yr growth
1-yr vs 3-yr growth
Sales Growth (1 Year)
Improving versus 3-year growth rate
-2.88%
Operating Profit Growth (1 Year)
Slowing versus 3-year growth rate
-27.27%
Net Profit Growth (1 Year)
Slowing versus 3-year growth rate
-30%
Asset Quality
Promoter Holding
52.30%
Pledged shares (%) of Promoter's holding (%)
0.00%
Reserves
-
Equity
₹6.4 Cr.
Face Value
₹10
All Time Low / High
₹0.50 / 12.00
10 Year X-Ray :
Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year endData adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
What is a Financial Track Record? How to read this chart in order to understand the data present here?
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Value Creation ⓘ
| Mar'05 | Mar'06 | Mar'07 | Mar'08 | Mar'09 | Mar'10 | Mar'11 | Mar'12 | Mar'13 | Mar'14 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | -6.9% | -14.4% | 3.8% | -6.8% | 1.5% | 9% | 2.7% | 2.4% | 2.7% | 1.9% | - |
Growth Parameters ⓘ |
|||||||||||
| Sales ⓘ | 1.1 | 1.1 | 1.4 | 1.3 | 1.4 | 1.3 | 1.2 | 1.2 | 1 | 1 | 1 |
| Sales YoY Gr. | - | 7.6% | 24.6% | -8.5% | 4.6% | -2.9% | -8.3% | -5% | -9.6% | -2.9% | - |
| Adj EPS ⓘ | -0.6 | -1.1 | 0.2 | -0.5 | 0 | 0.5 | 0.1 | 0.1 | 0.2 | 0.1 | 0.1 |
| YoY Gr. | - | NA | NA | -382.4% | NA | 1200% | -76.9% | 16.7% | 14.3% | -31.3% | - |
| BVPS (₹) ⓘ | 6.8 | 5.8 | 6 | 5.6 | 5.7 | 6.2 | 6.3 | 6.4 | 6.6 | 6.7 | 9.5 |
| Adj Net Profit ⓘ | -0.4 | -0.7 | 0.1 | -0.3 | 0 | 0.3 | 0.1 | 0.1 | 0.1 | 0.1 | 0 |
| Cash Flow from Ops. ⓘ | 0.2 | 0 | 0.2 | 0 | -0.1 | 0.1 | 0.6 | 0 | 0 | 0 | - |
| Debt/CF from Ops. ⓘ | 2.1 | 21.4 | 2.4 | 17.1 | -4.1 | 5.7 | 0 | 0 | 0 | 0 | - |
CAGR ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | -0.5% | -5.8% | -5.8% | -2.9% | ||||
| Adj EPS ⓘ | NA | 22.4% | -2.9% | -31.3% | ||||
| BVPSⓘ | -0.2% | 3.4% | 2.1% | 1.7% | ||||
| Share Price | - | - | - | - | ||||
Key Financial Parameters ⓘ
| Mar'05 | Mar'06 | Mar'07 | Mar'08 | Mar'09 | Mar'10 | Mar'11 | Mar'12 | Mar'13 | Mar'14 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | -8 | -16.5 | 2.3 | -5.6 | 0.5 | 6.1 | 1.3 | 1.5 | 1.8 | 1.2 | 1.4 |
| Op. Profit Mgn % ⓘ | -19.2 | -44.4 | 20.1 | -9.8 | 15.6 | 38.7 | 20.9 | 19.1 | 21.1 | 15.9 | 23.9 |
| Net Profit Mgn % ⓘ | -35.3 | -59.5 | 7.4 | -23.3 | 1.8 | 24.9 | 6.2 | 7.5 | 9.9 | 6.9 | 7 |
| Debt to Equity ⓘ | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0 | 0 | 0 | 0 | - |
| Working Cap Days ⓘ | 964 | 777 | 573 | 592 | 507 | 612 | 778 | 934 | 973 | 948 | 0 |
| Cash Conv. Cycle ⓘ | 593 | 482 | 317 | 348 | 332 | 421 | 475 | 253 | 216 | 615 | 0 |
Profit And Loss
(All Figures are in Crores.)| PARTICULARS | Mar'05 | Mar'06 | Mar'07 | Mar'08 | Mar'09 | Mar'10 | Mar'11 | Mar'12 | Mar'13 | Mar'14 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1.06 | 1.14 | 1.42 | 1.30 | 1.36 | 1.32 | 1.21 | 1.15 | 1.04 | 1.01 |
| Operating Expenses ⓘ + | 1.26 | 1.65 | 1.13 | 1.43 | 1.15 | 0.81 | 0.96 | 0.93 | 0.82 | 0.85 |
| Operating Profit ⓘ | -0.20 | -0.51 | 0.29 | -0.13 | 0.21 | 0.51 | 0.25 | 0.22 | 0.22 | 0.16 |
| Operating Profit Margin (%) | -19.2% | -44.4% | 20.1% | -9.8% | 15.6% | 38.7% | 20.9% | 19.1% | 21.1% | 15.9% |
| Other Income ⓘ + | 0 | 0 | 0 | 0.01 | 0 | 0 | 0 | 0.01 | 0.02 | 0.04 |
| Interest ⓘ | 0.03 | 0.04 | 0.05 | 0.02 | 0.04 | 0.04 | 0.04 | 0.01 | 0.01 | 0.01 |
| Depreciation ⓘ | 0.14 | 0.14 | 0.13 | 0.16 | 0.15 | 0.14 | 0.14 | 0.14 | 0.13 | 0.12 |
| Profit Before Tax ⓘ | -0.37 | -0.68 | 0.11 | -0.30 | 0.02 | 0.33 | 0.07 | 0.09 | 0.10 | 0.07 |
| Tax ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit After Tax | -0.37 | -0.68 | 0.11 | -0.30 | 0.02 | 0.33 | 0.07 | 0.09 | 0.10 | 0.07 |
| PAT Margin (%) | -35.3% | -59.5% | 7.4% | -23.3% | 1.8% | 24.9% | 6.2% | 7.5% | 9.9% | 6.9% |
| Adjusted EPS (₹) | -0.6 | -1.1 | 0.2 | -0.5 | 0.0 | 0.5 | 0.1 | 0.1 | 0.2 | 0.1 |
| Dividend Payout Ratio (%) | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Valuation of Perk Pharma - Standalone
Analyst's Notes
No data found!
Balance Sheet
(All Figures are in Crores.)| PARTICULARS | Mar'05 | Mar'06 | Mar'07 | Mar'08 | Mar'09 | Mar'10 | Mar'11 | Mar'12 | Mar'13 | Mar'14 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | |||||||||||
| Shareholders Fund + | 4.46 | 3.78 | 5.54 | 5.23 | 5.26 | 5.59 | 5.66 | 5.75 | 5.85 | 5.92 | |
| Debt + | 0.46 | 0.47 | 0.35 | 0.46 | 0.33 | 0.27 | 0.02 | 0.08 | 0.10 | 0.15 | |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Trade Payables | 0.27 | 0.30 | 0.32 | 0.37 | 0.25 | 0.32 | 0.84 | 0.20 | 0 | 0 | |
| Others Liabilities ⓘ | 0.79 | 0.76 | 0.67 | 0.48 | 0.17 | 0.52 | 0.56 | 0.58 | 0.04 | 0.07 | |
| Total Liabilities ⓘ | 5.97 | 5.32 | 6.88 | 6.55 | 6.01 | 6.71 | 7.08 | 6.61 | 5.99 | 6.14 | |
Fixed Assets | |||||||||||
| Net Fixed Assets ⓘ + | 3.05 | 2.95 | 4.47 | 4.27 | 4.02 | 3.88 | 3.81 | 3.21 | 3.09 | 2.86 | |
| CWIP ⓘ | 0 | 0 | 0 | 0 | 0.10 | 0.10 | 0.11 | 0 | 0 | 0.11 | |
| Investments ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Inventories | 1.55 | 1.24 | 1.21 | 0.93 | 0.70 | 0.68 | 0.61 | 0.51 | 0.47 | 0.41 | |
| Trade Receivables | 0.46 | 0.33 | 0.54 | 0.60 | 0.86 | 1.67 | 1.95 | 0 | 0.53 | 2.01 | |
| Cash Equivalents | 0.09 | 0.09 | 0.11 | 0.28 | 0.07 | 0.06 | 0.32 | 0.36 | 0.38 | 0.42 | |
| Others Assets ⓘ | 0.83 | 0.71 | 0.55 | 0.46 | 0.25 | 0.31 | 0.29 | 2.53 | 1.52 | 0.33 | |
| Total Assets ⓘ | 5.97 | 5.32 | 6.88 | 6.55 | 6.01 | 6.71 | 7.08 | 6.61 | 5.99 | 6.14 | |
Cash Flow
(All Figures are in Crores.)| PARTICULARS | Mar'05 | Mar'06 | Mar'07 | Mar'08 | Mar'09 | Mar'10 | Mar'11 | Mar'12 | Mar'13 | Mar'14 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash Flow From Operating Activity ⓘ + | 0.22 | 0.02 | 0.15 | 0.03 | -0.08 | 0.05 | 0.58 | 0 | 0 | 0 |
| Cash Flow From Investing Activity ⓘ + | -0.10 | -0.03 | -0.01 | 0.04 | -0 | -0 | -0.08 | 0 | 0 | 0 |
| Cash Flow From Financing Activity ⓘ + | -0.09 | 0.01 | -0.12 | 0.11 | -0.13 | -0.05 | -0.25 | 0 | 0 | 0 |
| Net Cash Flow ⓘ | 0.03 | 0 | 0.01 | 0.17 | -0.21 | -0.01 | 0.25 | 0 | 0 | 0 |
Financial Ratio
| PARTICULARS | Mar'05 | Mar'06 | Mar'07 | Mar'08 | Mar'09 | Mar'10 | Mar'11 | Mar'12 | Mar'13 | Mar'14 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | -8.28 | -16.91 | 2.79 | -8.18 | 0.69 | 8.69 | 1.88 | 2.13 | 2.49 | 1.64 |
| ROCE (%) | -6.85 | -14.35 | 3.75 | -6.84 | 1.53 | 9.01 | 2.71 | 2.39 | 2.72 | 1.91 |
| Asset Turnover Ratio | 0.17 | 0.2 | 0.23 | 0.19 | 0.22 | 0.21 | 0.19 | 0.17 | 0.17 | 0.17 |
| PAT to CFO Conversion(x) | N/A | N/A | 1.36 | N/A | -4 | 0.15 | 8.29 | 0 | 0 | 0 |
| Working Capital Days | ||||||||||
| Receivable Days | 140 | 124.50 | 112 | 159.80 | 195.90 | 347.30 | 511.90 | 0 | 185.20 | 456.50 |
| Inventory Days | 535.70 | 440.20 | 314.70 | 299.50 | 217.90 | 188.20 | 181.10 | 177.30 | 171.90 | 158.60 |
| Payable Days | 158.30 | 108.70 | 223.10 | 144.90 | 259.90 | 302.60 | 523 | 353.10 | 72.60 | 0.30 |
Management X-Ray
Shareholding Pattern
Promoter's Holding & Share Pledging
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
* Pledged shares as % of Promoter's holding (%)
Top 5 Mutual Funds Holding
Last Visited Stocks
Announcements
Perk Pharmaceuticals Ltd FAQs
The current trading price of Perk Pharma on 01-Jan-1970 05:30 is ₹0.00.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 31-Dec-1969 the market cap of Perk Pharma stood at ₹1.26 Cr
The latest P/E ratio of Perk Pharma as of 31-Dec-1969 is 18.12.
The latest P/B ratio of Perk Pharma as of 31-Dec-1969 is 0.21.
The 52-week high of Perk Pharma is ₹0.00 and the 52-week low is ₹0.00.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Perk Pharma is ₹1.01 ( Cr.) .
Data is not available for this company.
No data found
No data found
About Perk Pharmaceuticals Ltd
No data to display
To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
